Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Vertex Pharmaceuticals Inc., long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Net fixed asset turnover
Net fixed asset turnover (including operating lease, right-of-use asset)
Total asset turnover
Equity turnover

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Net Fixed Asset Turnover
The metric exhibited an overall upward trajectory from the first quarter of 2021 through to the end of 2024, increasing from 6.51 to a peak of 9.51 in the third quarter of 2024. Following this peak, there was a noticeable decline, with values decreasing to 8.23 by the third quarter of 2025. This trend indicates initially improving efficiency in generating sales from net fixed assets, though the later decline may suggest either an increase in asset base or reduced sales efficiency.
Net Fixed Asset Turnover (Including Operating Lease, Right-of-Use Asset)
This ratio generally followed a positive trend through 2021 and into 2023, rising from 4.90 to a high of 6.86 in the first quarter of 2024. However, unlike the standard net fixed asset turnover, there was a significant and sharp decline starting from the second quarter of 2024, dropping to 3.89 by the third quarter of 2025. This pronounced decrease could reflect changes in leasing practices or the capitalization of leases affecting asset values or sales.
Total Asset Turnover
The total asset turnover displayed a relatively stable but slightly declining pattern over the examined period. Starting at 0.53 in the first quarter of 2021, this ratio declined gradually to a low point around 0.43 across multiple quarters through 2023 and early 2024. A modest recovery was seen mid-2024, rising back to approximately 0.51, but it trended downwards again towards 0.47 by the third quarter of 2025. These fluctuations indicate relatively consistent but slightly weakening efficiency in using total assets to generate revenue.
Equity Turnover
Equity turnover showed a mild decreasing trend overall. From 0.71 in the first quarter of 2021, it declined to 0.55 by the first quarter of 2024. A temporary rebound occurred mid-2024 with values rising back near 0.7, though this was followed by a moderate decline to 0.68 by the third quarter of 2025. This pattern reveals varying effectiveness in utilizing shareholders' equity to produce revenue, with some cyclical improvement but no sustained upward momentum.

Net Fixed Asset Turnover

Vertex Pharmaceuticals Inc., net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Revenues
Property and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Net fixed asset turnover = (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024) ÷ Property and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data indicates a generally positive trend in revenues over the analyzed periods. Revenues show a steady increase from approximately 1.72 billion US dollars in the first quarter of 2021 to over 3.07 billion US dollars by the third quarter of 2025. This upward trajectory reflects consistent growth with a few fluctuations but no significant downward trends, suggesting effective revenue-generating activities and possibly successful market strategies or product performance.

In terms of property and equipment net values, there is a gradual increase from about 986 million US dollars in the first quarter of 2021 to around 1.43 billion US dollars by the third quarter of 2025. Despite some minor variations, the overall movement is upward, indicating ongoing investment or capital expenditure in fixed assets. Notably, there is a slight dip in the third quarter of 2024 compared to the previous quarter, but the value quickly rebounds in the following periods.

The net fixed asset turnover ratio reflects the efficiency with which the company is using its fixed assets to generate revenue. The ratio starts at 6.51 in the first quarter of 2021 and reaches a peak of 9.51 in the third quarter of 2024. This improvement suggests enhanced asset utilization over time. However, following the peak, there is a gradual decline to 8.23 by the third quarter of 2025. Although this decline indicates a slight reduction in efficiency, the ratio remains higher than the initial value, implying overall better asset management compared to the beginning of the period.

Revenues
Steady increase from approximately 1.72 billion to over 3.07 billion US dollars between Q1 2021 and Q3 2025, indicating sustained growth.
Property and Equipment, Net
Gradual rise from 986 million to about 1.43 billion US dollars, with minor fluctuations which suggest continuous investment in fixed assets.
Net Fixed Asset Turnover
Improved efficiency in asset utilization from 6.51 up to a peak of 9.51, followed by a modest decline to 8.23, remaining above the starting point.

Overall, the data suggests healthy financial performance characterized by revenue growth, consistent investment in fixed assets, and improved efficiency in using those assets to generate revenue, albeit with a slight recent decrease in asset turnover efficiency that may warrant monitoring.


Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Vertex Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Revenues
 
Property and equipment, net
Operating lease assets
Property and equipment, net (including operating lease, right-of-use asset)
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024) ÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + ) ÷ =


The analysis of the quarterly financial data reveals several notable trends and shifts in key performance metrics over time.

Revenues
The revenues demonstrate a generally increasing trend from March 2021 through September 2025. Starting at approximately 1.72 billion USD in the first quarter of 2021, revenues steadily rose, reaching around 2.98 billion USD by the third quarter of 2025. There are minor fluctuations, such as a slight dip in the fourth quarter of 2022, but the overall directional movement is upward, indicating sustained growth in sales over the evaluated periods.
Property and Equipment, Net (including operating lease, right-of-use asset)
The net book value of property and equipment, including operating leases, shows a progressive increase, particularly accelerating from June 2024 onwards. Initially, the figure hovered around 1.3 billion USD in early 2021, then grew moderately to about 1.45 billion USD by early 2023. Subsequently, a marked increase occurs reaching approximately 3.02 billion USD by the third quarter of 2025. This significant rise suggests substantial capital investments or acquisitions of fixed assets in the latter periods, enhancing the asset base considerably.
Net Fixed Asset Turnover (including operating lease, right-of-use asset)
This ratio, illustrating the efficiency of asset utilization in generating revenue, trends upward from early 2021 through early 2024, indicating improving efficiency. Starting at 4.9, it peaks around 6.86 in the first quarter of 2024, reflecting stronger revenue generation relative to the asset base. However, beyond that point, the ratio declines steadily to 3.89 by the third quarter of 2025. The reduction in turnover ratio coincides with the sharp increase in property and equipment value, suggesting that revenue growth is not keeping pace proportionally with asset expansion in the most recent periods, which may imply a period of resource underutilization or possibly the early phase of new assets deployment.

In summary, the revenue growth remains robust over the quarters analyzed, supported initially by increasing asset efficiency. However, the rapid expansion in asset base from mid-2024 impacts the fixed asset turnover negatively, signaling a need to monitor asset utilization closely going forward to ensure continued financial efficiency.


Total Asset Turnover

Vertex Pharmaceuticals Inc., total asset turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Revenues
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Total asset turnover = (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data reveals several noteworthy trends over the examined periods related to revenues, total assets, and total asset turnover ratio.

Revenues
Revenues have shown a general upward trend throughout the entire period, rising from approximately 1.72 billion to over 3.07 billion US dollars. This indicates consistent growth in the company's income generation capacity. The progression includes several intervals of steady quarterly increases, with minor fluctuations such as a slight dip toward the end of 2024, followed by a recovery and further growth into 2025. The data suggests resilience and an expanding operational scale.
Total Assets
Total assets have also increased significantly from about 12.1 billion in early 2021 to nearly 24.9 billion by late 2025. The increase was relatively steady but presents a notable challenge in mid-2024 when asset values dropped from 23.9 billion to around 20.1 billion, before resuming growth. This dip could reflect disposals, impairments, or restructuring activities. Overall, asset growth supports the expanded revenue base and indicates substantial investment in resources over time.
Total Asset Turnover Ratio
The total asset turnover ratio shows a declining trend over the years, decreasing from around 0.53 in early 2021 to approximately 0.47 in late 2025. This downward movement implies that the company is generating fewer revenues per unit of asset value than in prior periods. The reduced efficiency in asset utilization might arise from the rapid growth in asset base outpacing revenue increases, particularly visible during phases of accelerated asset accumulation. Despite the rising revenues, this ratio suggests a less efficient use of assets to generate sales.

In summary, the company demonstrates strong revenue growth alongside substantial asset expansion. However, the decreasing asset turnover ratio highlights a potential efficiency concern in how effectively assets translate into revenues, warranting further operational or capital allocation analysis to optimize asset utilization.


Equity Turnover

Vertex Pharmaceuticals Inc., equity turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Selected Financial Data (US$ in thousands)
Revenues
Shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

1 Q3 2025 Calculation
Equity turnover = (RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024) ÷ Shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data demonstrates consistent growth in revenues over the observed periods, with occasional fluctuations in quarter-to-quarter figures. Starting from approximately $1.7 billion in the first quarter of 2021, revenues exhibit an upward trajectory, reaching above $3 billion by the third quarter of 2025. Notably, the revenue increased steadily each year, reflecting a long-term positive sales trend despite minor quarterly variability.

Shareholders' equity also shows substantial growth throughout the timeline, increasing from around $9 billion in early 2021 to over $17 billion by late 2025. This growth indicates that the company's net assets and retained earnings have expanded significantly, suggesting strong internal capital accumulation or successful equity-raising activities. The equity growth trend aligns with revenue increases, implying overall business expansion and strengthening financial stability.

The equity turnover ratio, measuring revenue generated per dollar of equity, reveals a gradual decline initially from 0.71 in early 2021 to a low near 0.55 by the first quarter of 2024. This drop indicates that, during this period, revenue growth was relatively slower compared to the growth in shareholders’ equity, suggesting a reduced efficiency in using equity to generate revenues. However, following this period, the ratio rises again to approximately 0.68 by the third quarter of 2025, implying an improvement in equity utilization efficiency or relatively faster revenue growth compared to equity growth in recent quarters.

Overall, the company displays strong growth in both revenues and shareholders' equity over the examined quarters, with some cyclical variation. The initial decline in equity turnover ratio points to a phase of increasing equity base outpacing revenue growth, while the subsequent recovery in this ratio suggests improved operational efficiency or accelerated revenue gains relative to equity during the latest periods.

Revenues
Steady increase from approximately $1.7 billion (Q1 2021) to over $3 billion (Q3 2025), with minor quarterly fluctuations.
Shareholders’ equity
Growth from about $9 billion (Q1 2021) to nearly $17.3 billion (Q3 2025), indicating strengthened financial position and capital accumulation.
Equity turnover ratio
Decreased from 0.71 to 0.55 between 2021 and early 2024, then improved to 0.68 by late 2025, reflecting changing efficiency in generating revenue from equity.